Cover Image

CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer

PD-1 blockade therapy has made great breakthroughs in treatment of multiple solid tumors. However, patients with microsatellite-stable (MSS) colorectal cancer (CRC) respond poorly to anti-PD-1 immunotherapy. Although CRC patients with microstatellite instability (MSI) or microsatellite instability-h...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qi Lv (Author), Yishu Zhang (Author), Wen Gao (Author), Juan Wang (Author), Yaowen Hu (Author), Hongqiong Yang (Author), Ying Xie (Author), Yingshan Lv (Author), Heyuan Zhang (Author), Dapeng Wu (Author), Lihong Hu (Author), Junwei Wang (Author)
Format:	Book
Published:	Elsevier, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

M2 Macrophage Classification of Colorectal Cancer Reveals Intrinsic Connections with Metabolism Reprogramming and Clinical Characteristics
by: Huang F, et al.
Published: (2024)

LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases
by: Yanghe Zhang, et al.
Published: (2021)

Metabolic reprogramming in macrophage responses
by: Yang Liu, et al.
Published: (2021)

CSF-1-induced DC-SIGN+ macrophages are present in the ovarian endometriosis
by: Li Xiaocui, et al.
Published: (2022)

The influence of protein malnutrition on the production of GM-CSF and M-CSF by macrophages
by: Dalila Cunha de Oliveira, et al.

Reprogramming tumor-associated macrophages and inhibiting tumor neovascularization by targeting MANF-HSF1-HSP70-1 pathway: An effective treatment for hepatocellular carcinoma
by: Dan Han, et al.
Published: (2024)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
by: Lai CY, et al.
Published: (2021)

Galectin-1 Facilitates Macrophage Reprogramming and Resolution of Inflammation Through IFN-β
by: Hiba Yaseen, et al.
Published: (2020)

Sphingomyelin synthase 2 is a positive regulator of the CSF1R-STAT3 pathway in pancreatic cancer-associated macrophage
by: Shuhua He, et al.
Published: (2022)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
by: Liting Sun, et al.
Published: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment
by: Zhang Y, et al.
Published: (2023)

M2 macrophages-derived exosomes regulate osteoclast differentiation by the CSF2/TNF-α axis
by: Yue Zhou, et al.
Published: (2024)

Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress
by: Ziwei Li, et al.
Published: (2024)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024)

Reprogramming of macrophage metabolism and inflammatory injuries in chronic kidney disease
by: Jie Lyu, et al.
Published: (2024)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019)

Modulation of Airway Epithelial Innate Immunity and Wound Repair by M(GM-CSF) and M(M-CSF) Macrophages
by: Sander van Riet, et al.
Published: (2020)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023)

Tumor-Infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis
by: Tang D, et al.
Published: (2022)

CSF1 is expressed by the intestinal epithelial cells to regulate Mφ macrophages and maintain epithelial homeostasis and is downregulated in neonates with necrotizing enterocolitis
by: Xu Sun, et al.
Published: (2024)

CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
by: Qiao S, et al.
Published: (2024)

Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma
by: Yaojun Peng, et al.
Published: (2024)

Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation
by: Amy R. Johnson, et al.
Published: (2016)

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
by: Rongjie Zhang, et al.
Published: (2022)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019)

Diabetes Mellitus Inhibits Hair Follicle Regeneration by Inducing Macrophage Reprogramming-Mediated Pyroptosis
by: Wang M, et al.
Published: (2024)

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
by: Nan Zhang, et al.
Published: (2024)

Targeted systemic dendrimer delivery of CSF‐1R inhibitor to tumor‐associated macrophages improves outcomes in orthotopic glioblastoma
by: Kevin Liaw, et al.
Published: (2021)

PP 4.6 - 00065 Retinoic Acid Transcriptionally Reprograms Macrophages for Increased Permissiveness to HIV-1 Replication
by: J. Dias, et al.
Published: (2022)

Reprograming of Tumor-Associated Macrophages in Breast Tumor-Bearing Mice under Chemotherapy by Targeting Heme Oxygenase-1
by: Seung Hyeon Kim, et al.
Published: (2021)

Highly Selective MIF Ketonase Inhibitor KRP-6 Diminishes M1 Macrophage Polarization and Metabolic Reprogramming
by: Eszter Vámos, et al.
Published: (2023)

Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer
by: Wei-tong Zhang, et al.
Published: (2022)

Cancer Cell Secreted Legumain Promotes Gastric Cancer Resistance to Anti-PD-1 Immunotherapy by Enhancing Macrophage M2 Polarization
by: Xu Pei, et al.
Published: (2024)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022)

Macrophage Polarization and Reprogramming in Acute Inflammation: A Redox Perspective
by: Salvador Pérez, et al.
Published: (2022)

Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia
by: Yingying Wang, et al.
Published: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
by: Chuqi Lei, et al.
Published: (2023)